Phase 3

CRO

New non-compromise early-phase progression accelerator launched

Carbogen AMCIS introduces Sprint for early-phase development, a new, phase-appropriate approach designed to accelerate early-phase progression while maintaining scientific rigour. Sprint has been designed to...
Read more
Phase 3

AstraZeneca to seek accelerated approval of Ultomirisin in immunoglobulin A nephropathy on phase 3 data

AstraZeneca plans to seek accelerated approval of Ultomirisin kidney disease after the drug showed benefit after just 34 weeks, meeting its first primary endpoint. In...
Read more
Phase 3

Roche reports phase 3 study results for myelin oligodendrocyte glycoprotein antibody-associated disease

Roche has reported new findings from the phase 3 meteoroid trial of Enspryng (satralizumab) in adults and adolescents with myelin oligodendrocyte glycoprotein antibody-associated disease...
Read more
Phase 3

Novo Nordisk to seek oral sickle cell therapy approval after phase 3 success

A phase 3 trial of Novo Nordisk’s once-daily tablet has met both co-primary endpoints, reducing vaso-occlusive crises (VOC) and increasing haemoglobin (Hb) response in...
Read more
Phase 3

AstraZeneca to seek accelerated approval of Ultomirisin in immunoglobulin A nephropathy on phase 3 data

AstraZeneca plans to seek accelerated approval of Ultomirisin kidney disease after the drug showed benefit after just 34 weeks, meeting its first primary endpoint. In...
Read more
Phase 3

Roche reports phase 3 study results for myelin oligodendrocyte glycoprotein antibody-associated disease

Roche has reported new findings from the phase 3 meteoroid trial of Enspryng (satralizumab) in adults and adolescents with myelin oligodendrocyte glycoprotein antibody-associated disease...
Read more
Phase 3

Positive phase 3 topline results for oral infigratinib

BridgeBio Pharma, a biopharmaceutical company focused on developing medicines for genetic conditions, has announced positive topline results from Propel 3, the global phase 3...
Read more
Phase 3

Phase 3 antifungal trial cancelled over low response, higher mortality rate

Pulmocide’s phase 3 trial has been cancelled after patients who received its investigational inhaled antifungal had lower response rates and a higher number of...
Read more
- Advertisement -spot_img
- Advertisement -
EPO Summit ad
- Advertisement -
Pharmconex ad
- Advertisement -
NLS Days ad
- Advertisement -
ILMAC ad
- Advertisement -
BIO Europe

Latest posts

Load more

Drug Discovery & Development (DDD) is dedicated to advancing scientific innovations into active medical solutions. Its aim is to accelerate breakthroughs in medicine, addressing human disease and improving global health outcomes.

Menu

© Web design by Social Media Services 2026. All rights reserved.